LH
A new test, a bigger lane
Labcorp just announced it will offer the Elecsys pTau-217 test after the FDA cleared it. That makes it the first and only FDA-cleared single-biomarker blood test that can both help rule in and rule out amyloid pathology across specialty and primary care settings.
Why this matters
If you’re an investor, this is the kind of news that can quietly matter a lot. Alzheimer’s testing is a huge clinical need, and Labcorp is planting its flag in a more advanced corner of diagnostics instead of just being the lab that processes your routine bloodwork.
A few details that matter:
- The test measures phosphorylated Tau 217, a marker tied to amyloid pathology
- It’s intended for people 55 and older with signs or symptoms of cognitive decline
- Labcorp says the test can be used in both specialty and primary care settings
The business angle
This doesn’t magically turn Labcorp into a biotech moonshot, but it does give the company a more differentiated offering in a high-importance category. Tests like this can support volume, deepen physician relationships, and help Labcorp look a little less like a commodity lab business and a little more like a value-added diagnostics platform.
Big picture: if Alzheimer’s diagnostics keep moving from theory to routine clinical use, Labcorp wants to be in the middle of that shift—not standing on the curb watching the parade go by.